Assessment
tumor, Tumor
DISEASE PROGRESSION, TUMOR, METASTASES, TUMOR
Tumor assessment for study inclusion will be performed within 4 weeks prior to the first dose of study therapy and every eight weeks while treatment. The assessment will be performed by CT scan or MRI from chest to pelvis and all other sites of metastases and should continue until progression. Patients who discontinue trial therapy prior to disease progression should continue to have tumor assessments as per protocol schedule until progression. Tumor assessments are evaluated in accordance with to RECIST 1.1 [